thank joining today’s Once in quarter revenue us I all morning growth. call. had put you that task have excellent in to IRadimed reporting and exceptional Good again, of has and another for yet and earnings
of revenues. was revenue quarter top record QX ever our reported seventh we XXXX morning’s our consecutive this As quarter release. in and
the a first per ‘XX quarter increase $X.XX a earnings last release quarter non-GAAP diluted morning’s quarter $X.XX increase year. of first this in XXXX. XXXX the XX% first quarter at share, share earnings was per with share million reported over quarter of for were per the for diluted XX% As first revenue $XX.X over the first representing GAAP
CEO our for that feel The supply start issues record Still little just obstacles but growth. the a overcome have the a in become revenue from constant. proud raising continues more having in supply validate These team ways efforts to frequent upon the a team our such impacting to guidance those earnings to on comfortable and very at levels. and hard mitigate continue rather We stellar was bit. of finding which for year concerns a have these results make growth year
Looking at to bookings, to bookings perform well, backlog built products. continues QX maneuver total demand our driving issues for provides resources exceptionally sales supply allows continues record customer at team to excellent arise. us as The increasingly and may and Strong visibility be backlog through levels. our reallocate
pump was due large monitor revenue catching to compared as in up intake made to then be relatively QX. the was shortages pump part in rectified but QX, revenue not in example, which that QX a order to shipments For differences of could not rather due
the to like our XXXX team pump. touch would is MR efforts forth. FDA I putting and Now have IV expanded last Since regarding new been IRA our solid upon work quarter, much there we
for two end dates of hand occur three meetings. these written regarding next human FDA by We which intricate rather factors request appointment confirmations be received have weeks of yet so documents the in will Q-sub and We X that the Q-sub this fourth in should the plan far quarter. testing, detailed
content a background regarding to the from meeting a and propose as we supply application. in our a is to speak FDA information coming, for our FDA case FDA Q-sub for and that sort obtain buy clearance As the of to hopefully XXX(k) methods, in clarify to
or supported, requests. consider the given I indicated have additional need emails, as generally which be us to information and discussed that several that in AI previous FDA regarding calls letters and/or follow-up As had issues explained we
ahead okay with as meetings, approach these to exactly issues obtain increased our with their and push FDA pave be we meetings, am will answering the indication approach, will these expecting. our expeditious more clearly and with With that I issue each clearance. from FDA way information confidence our clarity AI is for our Q-sub they affirmatively now present to we and answer Q-sub what with as we AI is hope would subsequently more possible. file
level Now, like plus for will would and this given the to our performance revenue I recap our QX, that upward business trend outlook our performance in and great continue, of confidence increasing of earnings $X.XX revenue diluted per $X.XX million $X.XX. to to and GAAP non-GAAP earnings per of in expect $XX $XX.X We earnings share to now XXXX. of million. diluted $X.XX share
million, diluted the earnings $X.XX $X.XX. $XX.X GAAP report $XX.X of revenue per diluted second we share of quarter to $X.XX per $X.XX share expect earnings to of to For XXXX, non-GAAP and to
our Now, turn for to financial over CFO, the results will Jack? Glenn, the review more call the detail. Jack quarter to in I